OTTAWA, Jan. 2, 2020 /CNW/ - KML Foods is recalling Café Paris brand Soft Nougat ? Almond, Pistachio & Honey from the marketplace because it contains milk which is not declared on the label. People with an allergy to milk should not consume the recalled product described below.
The following product has been sold nationally.
Recalled product
Brand
Product
Size
UPC
Codes
Café Paris
Soft Nougat ? Almond, Pistachio & Honey
150 g
0 63493 33198 3
UCKCK
What you should do
Check to see if you have the recalled product in your home. Recalled products should be thrown out or returned to the store where they were purchased.
If you have an allergy to milk, do not consume the recalled product as it may cause a serious or life-threatening reaction.
This recall was triggered by a consumer complaint. The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.
The CFIA is verifying that industry is removing the recalled product from the marketplace.
Reactions
There has been one reported reaction associated with the consumption of this product.
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024. At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...